13.85
price down icon1.56%   -0.22
after-market 시간 외 거래: 13.85
loading
전일 마감가:
$14.07
열려 있는:
$14.07
하루 거래량:
75,116
Relative Volume:
0.60
시가총액:
$120.94M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-692.50
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
-6.73%
1개월 성능:
+87.16%
6개월 성능:
-5.27%
1년 성능:
-43.47%
1일 변동 폭
Value
$13.80
$14.68
1주일 범위
Value
$13.19
$15.50
52주 변동 폭
Value
$6.53
$29.40

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
명칭
Seres Therapeutics Inc
Name
전화
617 945 9626
Name
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Name
직원
103
Name
트위터
@SeresTX
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
MCRB's Discussions on Twitter

MCRB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MCRB
Seres Therapeutics Inc
13.85 129.68M 123.24M 136.00K -148.99M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-08 다운그레이드 Chardan Capital Markets Buy → Neutral
2024-10-24 다운그레이드 JP Morgan Neutral → Underweight
2023-06-26 재개 Oppenheimer Outperform
2023-04-21 개시 JP Morgan Neutral
2021-07-23 다운그레이드 Goldman Neutral → Sell
2021-05-18 재개 Goldman Neutral
2021-03-05 업그레이드 Chardan Capital Markets Neutral → Buy
2020-09-18 다운그레이드 Chardan Capital Markets Buy → Neutral
2020-08-18 개시 Piper Sandler Overweight
2020-08-11 재확인 H.C. Wainwright Buy
2020-08-11 업그레이드 Jefferies Hold → Buy
2019-04-30 개시 Jefferies Hold
2018-10-22 개시 Chardan Capital Markets Buy
2017-10-13 개시 Oppenheimer Outperform
2017-08-04 재확인 H.C. Wainwright Buy
2017-02-01 재확인 FBR & Co. Outperform
2016-08-12 재확인 FBR Capital Outperform
2016-08-01 다운그레이드 BofA/Merrill Buy → Neutral
2016-08-01 재확인 H.C. Wainwright Buy
2016-07-29 재개 H.C. Wainwright Buy
2016-03-30 개시 FBR Capital Outperform
2016-03-03 개시 Guggenheim Buy
2016-01-25 개시 H.C. Wainwright Buy
2015-10-22 업그레이드 BofA/Merrill Neutral → Buy
2015-07-22 개시 Canaccord Genuity Buy
2015-07-21 개시 Goldman Neutral
2015-07-21 개시 Leerink Partners Outperform
모두보기

Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스

pulisher
11:51 AM

Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions - Yahoo Finance

11:51 AM
pulisher
Jul 20, 2025

Is Seres Therapeutics Inc. a good long term investmentOutstanding investment returns - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Seres Therapeutics Inc. stock priceBreakthrough capital growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Seres Therapeutics Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Seres Therapeutics Inc. stockDynamic investment opportunities - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest

Jul 14, 2025
pulisher
Jul 01, 2025

5 Best Microbiome Companies (July 2025) - Securities.io

Jul 01, 2025
pulisher
Jun 30, 2025

Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com

Jun 25, 2025
pulisher
Jun 12, 2025

FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus

Jun 12, 2025
pulisher
Jun 02, 2025

Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.

Jun 02, 2025
pulisher
May 28, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World

May 28, 2025
pulisher
May 27, 2025

Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics reports promising biomarker data - Investing.com

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

May 23, 2025
pulisher
May 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World

May 17, 2025
pulisher
May 16, 2025

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts

May 16, 2025
pulisher
May 12, 2025

Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com

May 12, 2025
pulisher
May 11, 2025

Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World

May 11, 2025
pulisher
May 09, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World

May 09, 2025
pulisher
May 08, 2025

Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga

May 08, 2025
pulisher
May 08, 2025

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com

May 08, 2025
pulisher
May 08, 2025

Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks

May 07, 2025
pulisher
May 07, 2025

Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025

Seres Therapeutics Inc (MCRB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):